Research programme: small molecule inhibitors - Eilean Therapeutics
Latest Information Update: 08 Sep 2023
At a glance
- Originator Eilean Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 25 Aug 2023 Early research in Cancer in USA (unspecified route) before August 2023 (Eilean Therapeutics pipeline, August 2023)